AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01387867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Supervised strength training in groups 2 x 1 hour weekly and un-supervised strength training 1 hour weekly for 4 months
Study NCT01387867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: Supervised Nordic Walking in groups 2 x 1 hour weekly and un-supervised Nordic Walking 1 hour weekly for 4 months
Study NCT01387867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised home based exercise
Description: Unsupervised home based exercise as recommended by the Danish Arthritis Association 1 hour 3 x weekly for 4 months
Study NCT04466176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product
Description: 2 inhalations of Test and Reference product in each study period
Study NCT04466176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: 2 inhalations of Test and Reference product in each study period
Study NCT03616132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System
Description: Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
Study NCT03849807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: the intervention group will receive 4 weeks of chiropractic care along with usual care(Cognitive-Behavioral, psychosocial Therapy).
Study NCT03849807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants in the group will receive usual health (Cognitive-Behavioral, psychosocial Therapy) care or wish to engage in during the course of the study as well as receiving a passive movement control intervention delivered by a chiropractor 3 times per week in the same hospital setting as the group receiving chiropractic care.
Study NCT03499548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INSPiRe Programme
Description: Intensive CBT for suicide
Study NCT03369470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App Dexterity
Description: App based dexterity training by means of Finger Zirkus (see for more details: www.fingers-in-motion.de)
Study NCT03369470 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Theraband
Description: Active control being five traditional hand strengthening (Thera-band) exercises, which we published in our previous RCT, being feasible and effective in improving dexterity (for more details see for Kamm et al. 2015).
Study NCT03901547 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Communication Skills Training
Description: Education training in the serious illness communication guide (SICG) by Ariadne labs.
Study NCT03901547 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Profile feedback
Description: Providing participants their personal documentation rate of SICG in the electronic medical record
Study NCT03901547 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Maslach burnout inventory
Description: Maslach burnout inventory
Study NCT03901547 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emotion Regulation Skills Question (ERSQ)
Description: This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL). This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL).
Study NCT03901547 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Semi-structured interview
Description: Interviewer asked subjects are a series of questions based on interview guide. Current guide designed to assess subject perception of implementation of training in clinical encounters, most recent encounter with patient with serious illness, barriers to documentation and coaching by faculty on communication. Interviews will be recorded and expected duration is 20-40 minutes.
Study NCT03901547 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Priming
Description: Participants will be provided a list of 30 patients they have encountered before that 1) have at least one documented note and 2) have a high probability for having serious illness as determined by electronic medical record screening. Participants will be asked 4 yes or no questions on each patient. Questions: 1) do you believe this patient has serious illness?; 2) would you be surprised if this patient died in the next year?; 3) would the patient benefit from the serious illness conversation guide? and 4) If you saw this patient again, would you use the serious illness conversation guide with him/ her?
Study NCT02841436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation (IRE) System
Study NCT05099081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diode laser application
Description: Local anesthesia will be applied Lesion will be excised with diode laser (Medency, Italy) continuous wave mode 980 nm wave length with an output power 3 W in contact mode
Study NCT05099081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intra-lesional injection of ethanolamine oleate
Description: Local anesthesia will be applied Injection of ethanolamine oleate (sclerosing gent) with concentration 5% diluted in distilled water to form 2.5% ethanolamine oleate According to lesion size range from 1.5 to 3 ml of solution will be injected slowly into lesion using gauge needle until leaked from lesion.~Lesion will be compressed for 5 minutes. Lesion will be observed once a week after injection until it becomes necrotic and falls off spontaneously.~Repeated injection may be needed.
Study NCT02848170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150
Description: CS-3150 2.5mg, oral
Study NCT02848170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olmesartan medoxomil
Description: olmesartan medoxomil 10 mg, oral
Study NCT00515177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: The intervention is a standardized program of mindfulness training led by an instructor. 8 weekly 2.5 hours sessions provide information on stress, cognition and health and training in a variety of mindfulness techniques including gentle yoga, body scan and sitting meditations. The program includes homework and home practice of mindfulness.
Study NCT00515177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eszopiclone
Description: One 3 mg tablet of eszopiclone nightly for 8-weeks followed by 3-months of as needed use
Study NCT01967342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Ed
Description: A 10-week psychosocial group treatment for chronic pain that focuses on providing information about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to take ownership of their chronic pain care through building deeper knowledge about their pain condition and their interactions with the health care system.
Study NCT01967342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Pain
Description: A 10-week psychosocial group treatment for chronic pain that focuses on providing information and skills about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to self-manage their chronic pain through building deeper knowledge about and better skills for improving their pain condition and their interactions with the health care system.
Study NCT01967342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: A comparison condition in which patients receive standard individualized medical care from the federally qualified health center partnering on this study. Care can include basic biological interventions, such as medication or surgery, as well as supplementary care such as chiropractic or physical therapy. However, cost has a pragmatic influence on the amount of services provided, sought, and received.
Study NCT01967342 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: A comparison condition in which patients receive standard individualized medical care from the federally qualified health center partnering on this study. Care can include basic biological interventions, such as medication or surgery, as well as supplementary care such as chiropractic or physical therapy. However, cost has a pragmatic influence on the amount of services provided, sought, and received.
Study NCT01975961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC
Description: For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.
Study NCT03227133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluations
Description: Neuropsychological evaluations including oral fluency, performed specifically for the study
Study NCT03227133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychiatric interview
Study NCT03227133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk assessment
Study NCT01975961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC
Description: For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.
Study NCT00678327 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bleomycin sulfate
Description: Given IV
Study NCT00678327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV
Study NCT00678327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study NCT00678327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given subcutaneously
Study NCT00678327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00678327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine
Description: Given IV
Study NCT00678327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00678327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT02759809 — intervention group
Intervention type: OTHER
Intervention: Pasteurized donor human breastmilk
Study NCT02759809 — intervention group
Intervention type: OTHER
Intervention: Preterm formula
Study NCT03026777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous crystalloid fluid, 500 mL
Study NCT00779610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vibration with flexion
Description: Vibration with forearm flexion (active contraction)
Study NCT00779610 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vibration without flexion
Description: Vibration without forearm flexion (passive)
Study NCT03914833 — intervention group
Intervention type: OTHER
Intervention: Inclusion Questionnaires
Description: During the inclusion visit, neuropsychologist tests the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Scale) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
Study NCT03914833 — intervention group
Intervention type: OTHER
Intervention: Questionnaires at inclusion, M1 and M3
Description: During the inclusion visit, the 1-month visit and the 3-month visit; neuropsychologist grading of the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Index) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
Study NCT04297735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care group
Description: Visits every 6 months is standard of care.
Study NCT04297735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine group
Description: Conduct monthly telemedicine 'skype' visit
Study NCT04297735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Review details of medication indication and use, activity recommendations and changes, and knowledge of arrhythmia changes and activities which are helpful with arrhythmia changes.
Study NCT00500331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: Experimental Drug
Study NCT00500331 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pioglitazone
Description: Active Control
Study NCT00500331 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT02117271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure
Description: device to treat obstructive sleep apnea using positive airway pressure with a nasal mask
Study NCT02117271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Breathe Right ®
Description: Nasal dilator strip treatment used during sleep to open the nasal airway
Study NCT03823508 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal tDCS
Description: Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and a high density EEG. The anode will be placed over F3 in order to stimulate the left dorsolateral prefrontal cortex and the cathode over the right supraorbital area.
Study NCT03823508 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tDCS
Description: Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
Study NCT06429111 — intervention group
Intervention type: PROCEDURE
Intervention: Epidural analgesia
Description: Consists of a central nerve block by injecting a local anesthetic near the nerves that transmit pain, in the lumbar region, for pain relief during labor.
Study NCT06429111 — intervention group
Intervention type: PROCEDURE
Intervention: Immersion water
Description: Consists of the use of hot water immersion in a birthing tub during labor and/or delivery.
Study NCT02575131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole wheat bread yeast basis
Study NCT02575131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal
Study NCT04502108 — intervention group
Intervention type: BEHAVIORAL
Intervention: Covid19
Description: Impact of the COVID19-pandemic on physical activity, nutritional habits and sleeping behavior during an extraordinary period of confinement and social distancing, during the loosening phase and social distancing and the phase after the pandemic.
Study NCT04336566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin 5mg
Study NCT04336566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparable Good Neighbor Pharmacy placebo tablet
Study NCT02264756 — intervention group
Intervention type: OTHER
Intervention: ASP review
Description: patients admitted to hospital with a diagnosis of community-acquired pneumonia will be reviewed by team members of antimicrobial stewardship program and subsequently feedback to attending physicians will be offered in the form of recommendations for antibiotic management
Study NCT02575131 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cheerios
Study NCT02575131 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole wheat sourdough bread
Study NCT02575131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard breakfast
Study NCT00658008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Capsules, oral, 175 mg BID, 8 weeks with 2 week taper
Study NCT00658008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
Study NCT00658008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Capsules, oral, 75 mg BID, 8 weeks with 2 week taper
Study NCT00658008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Capsules, oral, Paroxetine 20 mg QD, 8 weeks with 2 week taper
Study NCT00658008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, oral, placebo bid, 8 weeks with 2 week taper
Study NCT02884531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education and Basic Body Awareness Therapy
Description: Patient education (1/2 day) and a Physiotherapy movement modality (12 times, once a week)
Study NCT02884531 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: Patient education (1/2 day)
Study NCT02884531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Patient education (1/2 day)
Study NCT03277690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Description: During the double-blind Withdrawal Phase, patients will receive up to 1200 mg levoketoconazole daily.~During the double-blind Restoration Phase, patients will receive levoketoconazole plus placebo.
Study NCT03277690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the double-blind Withdrawal Phase, patients will receive placebo tablets.~During the double-blind Restoration Phase, patients will receive placebo plus levoketoconazole.
Study NCT00550849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402
Description: 5 mg oral capsules
Study NCT00550849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402
Description: 25 mg oral capsules
Study NCT00550849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402
Description: 50 mg oral capsules
Study NCT01691898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles.
Study NCT02870543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phytolacca decandra
Description: Treatment of bruxism
Study NCT02870543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melissa officinalis
Description: Treatment of bruxism
Study NCT02870543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melissa officinalis
Description: Treatment of bruxism
Study NCT02870543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melissa officinalis
Description: Treatment of bruxism
Study NCT02870543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phyt.decandra + Melissa offic.
Description: Treatment of bruxism
Study NCT02870543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phyt.decandra + Melissa offic.
Description: Treatment of bruxism
Study NCT02551354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable video pupillometer
Description: Portable video pupillometer measures pupil diameter (PD) in patient during obstetrical labor
Study NCT02611648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Double HLD
Description: Standard high level disinfectant (metricide ortho-phthalaldehyde) with an additional exposure time to disinfect
Study NCT02611648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HLD/ETO
Description: Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
Study NCT00361309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks).
Study NCT02856711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-informed group
Description: The two interventions will be: 1) A viewing of All Babies Cry and a discussion of what it's like to be a new parent, 2) A Planning to Parent stress activity where parents discuss when they have felt overwhelmed, the coping mechanisms they used, and what can be done to manage those emotions in the future. The goal of this project is to gain insight from current participants in CenteringPregnancy group care around the ways that these interventions can better prepare parents to deal with the common stresses of parenthood.
Study NCT02611414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tDCS
Description: tDCS anodal stimulation over M1 area applied for 20 minutes at five consecutive days.
Study NCT02611414 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: tDCS sham stimulation over M1 applied for 20 minutes (with current turned off at 30 seconds) at five consecutive days.